Researchers at the University of Kumamoto in Japan have developed a novel blood test that detects breast cancer recurrence by analyzing nucleosomes—structures in which DNA wraps around proteins—rather than tracking genetic mutations alone. Published in Cancer Research Communications, this minimally invasive method aims to monitor patients during and after treatment.
A team at the University of Kumamoto has turned its attention to nucleosomes to catch molecular shifts.
Understanding Nucleosomes and Circulating DNA
Published in the journal Cancer Research Communications, the study analyzed cell-free DNA (cfDNA) extracted from 150 blood samples. This cohort included 105 samples from primary breast cancer cases and 45 from patients with recurrent or metastatic disease. Instead of just hunting for changes in the DNA sequence, the investigators mapped how DNA packages itself around histone proteins.
These structures are known as nucleosomes. Their arrangement reflects how genes are regulated and the degree of packaging of DNA regions. When breast cancer cells acquire resistance to hormonal therapy, these regions experience transcriptional changes. By examining these structural packaging patterns in blood, clinicians can spot changes associated with treatment resistance and recurrence.
The research team zeroed in on 26 genomic regions known to undergo transcriptional changes during hormone therapy resistance. They discovered that recurrent breast cancer was associated with a higher number of genetic variants alongside shorter cfDNA fragments. Two specific regions, designated as RERE and SYNPO2, stood out for the researchers.
Clinical Accuracy and Diagnostic Potential
To quantify these structural differences, the team generated a nucleosome-based score derived from the RERE and SYNPO2 genomic regions. This score differentiated primary breast cancer from recurrent disease with an area under the curve (AUC) of 0.826, indicating a high discriminatory capacity in this study.
When researchers combined this nucleosome information with other characteristics of cell-free DNA, the prediction of recurrence improved further. Because cfDNA is harvested via a blood sample, this method could contribute to the minimally invasive monitoring of patients during and after treatment, potentially facilitating early detection of recurrence and more personalized therapeutic decisions.
Despite these findings, the study relied on a retrospective cohort that was relatively limited. Investigators noted that larger prospective studies are required to determine the applicability of this approach in clinical practice. These studies must address differences in breast cancer subtypes and patient backgrounds between the groups.
In Plain English: The Clinical Takeaway
- Liquid Biopsy: A blood draw captures floating DNA fragments released into the bloodstream.
- Beyond Mutations: Instead of searching only for genetic mutations, this test looks at how DNA is wrapped (nucleosomes), revealing changes in genetic regulation and chromatin structure.
- Early Warning: The method differentiated primary cancer from returning cancer in retrospective samples, pointing toward future monitoring tools.
References
- Cancer Research Communications. University of Kumamoto.
